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ABSTRACT
Objective To examine quality of life (QoL) and other 
patient- reported outcome measures (PROMs) in kidney 
transplant recipients and those awaiting transplantation.
Design Longitudinal cohort questionnaire surveys and 
qualitative semi- structured interviews using thematic 
analysis with a pragmatic approach.
Setting Completion of generic and disease- specific 
PROMs at two time points, and telephone interviews with 
participants UK- wide.
Participants 101 incident deceased- donor (DD) and 94 
incident living- donor (LD) kidney transplant recipients, 
together with 165 patients on the waiting list (WL) from 
18 UK centres recruited to the Access to Transplantation 
and Transplant Outcome Measures (ATTOM) programme 
completed PROMs at recruitment (November 2011 to 
March 2013) and 1 year follow- up. Forty- one of the 
165 patients on the WL received a DD transplant and 
26 received a LD transplant during the study period, 
completing PROMs initially as patients on the WL, and 
again 1 year post- transplant. A subsample of 10 LD and 10 
DD recipients participated in qualitative semi- structured 
interviews.
Results LD recipients were younger, had more 
educational qualifications and more often received a 
transplant before dialysis. Controlling for these and other 
factors, cross- sectional analyses at 12 months post- 
transplant suggested better QoL, renal- dependent QoL and 
treatment satisfaction for LD than DD recipients. Patients 
on the WL reported worse outcomes compared with 
both transplant groups. However, longitudinal analyses 
(controlling for pre- transplant differences) showed that 
LD and DD recipients reported similarly improved health 
status and renal- dependent QoL (p<0.01) pre- transplant to 
post- transplant. Patients on the WL had worsened health 
status but no change in QoL. Qualitative analyses revealed 
transplant recipients’ expectations influenced their 
recovery and satisfaction with transplant.
Conclusions While cross- sectional analyses suggested 
LD kidney transplantation leads to better QoL and 
treatment satisfaction, longitudinal assessment showed 
similar QoL improvements in PROMs for both transplant 
groups, with better outcomes than for those still wait- 
listed. Regardless of transplant type, clinicians need to be 
Strengths and limitations of this study
 ► We examined a number of patient- reported out-
comes in people requiring kidney transplantation, 
including quality of life, well- being, treatment satis-
faction and health status.
 ► We collected pre- transplant data for a subsample of 
deceased- donor and living- donor kidney transplant 
recipients while they were still waiting for a trans-
plant, and assessed outcomes from pre- transplant 
to 1 year post- transplant.
 ► Controlling for various medical and demographic 
factors, including age, time on dialysis and educa-
tion, impacts the findings, removing apparent ben-
efits of living- donor kidneys over deceased- donor 
kidneys.
 ► The sample of kidney transplant recipients with pre- 
transplant data is relatively small (n=67 including 
26 with living donors and 41 with deceased donors).
 ► Longer follow- up may be required to examine 
fully any differences in PROMs between groups 
post- transplant.
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aware that managing expectations is important for facilitating patients’ 
adjustment post- transplant.
INTRODUCTION
Healthcare usually aims to improve health and mini-
mise disability,1 and there is growing acknowledgement 
that patient- reported outcome measures (PROMs) are 
important for evaluating the effectiveness of health-
care. PROMs are measures of outcomes that are directly 
reported by the patient, and are usually questionnaires 
that can be generic or condition- specific. PROMs may 
measure a wide range of outcomes including health 
status, quality of life (QoL), treatment satisfaction, well- 
being and other outcomes such as symptoms. Despite 
their importance in assessing the patient’s perspective, 
PROMs such as QoL are not measured routinely as part 
of the evaluation of surgical interventions.1 Part of the 
reason for this has been the belief that brief health- status 
tools (such as the EuroQoL- 5D (EQ- 5D) capture QoL,1 as 
well as the time and cost involved in collecting and inter-
preting the data.2 3 However, PROMs other than health 
status tools have an important role in clinical care3 as 
they may determine the comparative benefits of different 
medical interventions used to treat the same condition.4
One example of a condition that can benefit from 
the measurement of PROMs is advanced chronic kidney 
disease (CKD Grade (G) 5). Kidney transplantation 
is commonly considered to be the best medical treat-
ment for most people with advanced CKD G5 who are 
fit enough for the procedure.5 Recent changes to the 
kidney donor system, such as deemed consent legislation 
in Wales since 2015, and a similar system introduced in 
England in May 2020, and due to be enacted in Scotland 
in 2021, aim to increase the number of deceased- donor 
(DD) kidneys available.6 Kidney transplant waiting times 
have also reduced in recent years due to an increase in 
unrelated living donation including altruistic donation, 
and kidney sharing schemes that allow for greater access 
to living- donor (LD) transplantation for blood- group or 
human- leucocyte- antigen- incompatible donor- recipient 
pairs.7 Transplantation success is most often measured by 
patient and graft survival and as such LD transplantation 
provides a greater survival advantage when compared 
directly with DD transplantation, controlling for differ-
ences in variables such as age8 and time on dialysis.9 LD 
transplantation is associated with lower rejection rates7 
and spares individuals the uncertain wait for a deceased- 
donor organ.7 However, it is important to note that LD 
recipients tend to have better clinical indices of health 
pre- transplant.10 11 These potential confounding factors 
can impact graft survival,12 so pre- transplant differences 
between LD and DD recipients should be measured and 
controlled, before comparisons are made between the 
groups. The other issue apparent with these studies is 
that they focus on the comparative benefits of LD and DD 
transplantation for health, but not for other outcomes 
such as QoL.
When PROMs have been assessed in kidney trans-
plantation, cross- sectional post- transplant comparisons 
indicated that LD recipients reported greater social 
involvement and happiness compared with DD recip-
ients.12 When cross- sectional data are analysed, it is 
important to have well- matched controls but in prac-
tice that is difficult to achieve because those who are 
left on the waiting list for deceased- donor kidneys tend 
to have more health problems than those who receive a 
transplant. Studies that have controlled for underlying 
differences across the groups, such as differences in age 
or comorbid disease, report similar outcomes for both 
transplant groups on health status measures such as the 
SF-36,13 although many LD recipients report experiencing 
feelings of guilt about the risks to their donor.14 15 Longi-
tudinal studies, which can include and control for base-
line measures of outcomes before participants receive a 
transplant, suggest that improvements in health status 
can be seen in the first few months post- transplant for 
both DD and LD, but that these improvements remain 
stable after this time.16–19 However, these studies lack any 
group with which to compare transplant recipients, such 
as those still awaiting transplantation, and not all include 
data pre- transplant. Those who are transplanted are more 
likely to be in better health than those patients still wait- 
listed for a transplant, so it is important to control for 
baseline differences between participants who receive a 
transplant and those who do not.
One major problem with all of these studies is that 
the instruments used to measure QoL such as the SF-36, 
actually measure health status.20 Health status includes 
aspects of a person’s life such as their physical ability, 
daily functioning and experience of symptoms. Health- 
related QoL is a term that is commonly and misleadingly 
used to refer to health status tools such as the SF-36 and 
EQ- 5D, which may assess health and functioning but do 
not assess the impact of health and functioning on QoL. 
In contrast, QoL as measured by the renal- dependent 
QoL (RDQoL) measure used in Access to Transplanta-
tion and Transplant Outcome Measures (ATTOM),21 is 
defined within the questionnaire as ‘how good or bad 
you feel your life to be’. RDQoL, modelled on the Audit 
of Diabetes Dependent Quality of Life (ADDQoL) for 
diabetes22 and influenced by McGee et al’s23 individual-
ised interview method of generic QoL measurement, 
establishes the relevance of different aspects of life for 
each individual respondent and excludes non- relevant 
items from the scoring. It allows for individual differ-
ences in the importance of relevant aspects of life for 
QoL as well as measuring the impact of the renal condi-
tion on each relevant aspect of life. Impact is weighted by 
importance and an average weighted impact (AWI) score 
obtained for each individual indicating the nature and 
extent of the impact of the renal condition on the individ-
ual’s QoL. A single item to measure generic QoL is also 
included in the measure and this item can be expected to 
be more strongly related to health status generally than 
the condition- specific AWI score.24 Given the confusion 
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surrounding the definitions and measurement of these 
concepts, it is important that research includes genuine 
measures of QoL and condition- dependent QoL as well 
as a health status measure when investigating PROMs in 
people with CKD. The addition of qualitative research 
methods alongside PROMs, can be valuable in providing 
more detailed insight into how transplant recipients 
experience transplantation and how it impacts QoL.
The main objectives of the present study were (1) to 
examine QoL (generic and condition- dependent), health 
status and other PROMs in recipients of DD or LD trans-
plants, and (2) to compare them over time with those on 
the waiting list (WL) for a DD transplant in a matched 
cross- sectional cohort and in a subsample with longitu-
dinal data pre- transplant and post- transplant. Specifi-
cally, it was hypothesised that, controlling for potential 
confounding factors, there would be very few differences 
in outcomes between DD and LD recipients. It was also 
hypothesised that transplant recipients would report 
less negatively impacted QoL and better scores on other 
PROMs than participants waiting for a transplant. The 
third objective was to use qualitative interview methods to 
explore in more depth the expectations and experience 
of transplantation and how it influences QoL 1 year post- 
transplant in DD and LD transplant recipients.
METHODS
Study design, participants and procedure
This study employed a longitudinal cohort survey design, 
as well as a qualitative interview approach. The study was 
part of the UK ATTOM research programme.25 ATTOM 
was based on a large national observational cohort study 
involving all kidney units in the UK in order to examine 
the reasons for disparities in access to renal transplanta-
tion.26 27 Full ATTOM methodology has been reported 
elsewhere.25 The current study was conducted within 
a work- stream examining detailed PROMs in patients 
fluent in English, aged less than 75 years, receiving renal- 
replacement therapy (RRT) who completed measures of 
health status, well- being, QoL and treatment satisfaction. 
Qualitative interviews were conducted with a subset of 
patients 1 year post- transplant.
Following ethical approval (East of England Research 
Ethics Committee 11/EE/0120), and informed consent, 
participants were recruited by ATTOM research nurses 
to the study as incident recipients of DD transplants 
(n=104), incident LD transplant recipients (n=94) or 
patients on the WL for a transplant (n=165) and followed 
up either 1 year post- recruitment or 1 year post- transplant 
(figure 1). Across 18 UK renal centres, a subset of partic-
ipants recruited to ATTOM were recruited to this work- 
stream. The first eligible patient for each transplant 
group seen each month (November 2011 to March 
2013) by each nurse was invited to take part. Inclusion 
criteria were fluency in English and <75 years of age. 
Participants were recruited if they had G5 CKD and 
received a DD or LD transplant within 1 month. The UK 
Transplant Registry identified possible matched controls 
for recruited transplant recipients every 2 weeks, and 
members of this list of potential participants were then 
invited to take part as patients on the WL. Participants 
on the WL were matched to DD transplant recipients as 
closely as possible in terms of renal centre, age (±5 years), 
time on the WL (±100 days) and previous type of RRT. 
Participants completed measures of health status and 
well- being when first recruited to ATTOM by the research 
nurses, and measures of generic and renal- dependent 
QoL, and renal treatment satisfaction 3 months post- 
transplant/post- recruitment via telephone or post. A 
timeframe of 3 months was chosen to allow participants 
time to experience their treatment (ie, transplant for 
those receiving a transplant) and be able to reflect on 
how their QoL and treatment satisfaction were impacted 
after their return home for those having surgery. At 
1 year, participants were contacted via telephone and 
completed all measures again (via telephone or post), 
as well as a measure of change in treatment satisfaction 
which compared satisfaction with current renal treat-
ment and previous renal treatment. One- year follow- up 
was chosen because it would be expected that clinical 
outcomes would be stable 1 year post- transplant, but it 
is not clear whether non- clinical outcomes (ie, PROMs) 
would also remain stable. At the same time, choosing 
1 year follow- up allows for comparisons to be made with 
previous research that has examined health status using 
the same timeline. A sample of 100 participants in each 
of the three groups was calculated as adequate to reach 
80% power within the planned analyses. Some of the 
participants recruited as patients on the WL subsequently 
received a DD (n=41) or LD kidney transplant (n=26) in 
the year of follow- up. For these participants, the initial 
measures were completed while they were still on the WL, 
giving a pre- transplant measure, and the second set of 
measures was completed 1 year post- transplant (figure 1). 
These data allowed for secondary analyses in patients for 
whom we had true baseline measures comparing the two 
transplant groups and those remaining on the waiting list 
pre- transplant and post- transplant. Participants recruited 
as WL comparison patients who went on to receive a 
transplant within ATTOM were not asked to complete the 
measures at 3 months post- transplant in the same way as 
those recruited to the study as transplant recipients were 
asked to do. It was not always possible to contact people 
within 3 months of receiving their transplant once they 
had been recruited as patients on the WL, and a limit of 4 
points of data collection were set for each participant, to 
minimise participant burden.
A subset of transplant recipients was selected for qual-
itative telephone interviews. The aim of this qualita-
tive study was to explore the experience of receiving a 
transplant, and how having a transplant affects QoL and 
other PROMs. The sample consisted of 10 DD transplant 
and 10 LD transplant recipients. All participants had 
been contacted previously by authors (AG or JB) when 
arranging completion of questionnaires. Participants 
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were invited to take part based on their AWI scores on 
the RDQoL questionnaire,21 completed 1 year post- 
transplant. Participants with AWI scores above or below 
one SD of the mean score, as well as those with a mean 
score, were included so that participants had varying levels 
of QoL. The qualitative sample was selected on the basis 
of QoL scores to aid our understanding of the range of 
responses and how they may relate to variations in QoL. 
The profile of the qualitative- study participants reflected 
the age and sex profile of the larger sample. Participants 
were informed that the interview would explore their 
questionnaire responses related to their QoL and treat-
ment satisfaction. Semi- structured telephone interviews 
were conducted between January and August 2014, and 
were conducted by a single interviewer using an inter-
view schedule (online supplemental data 1) guided by 
published literature and participants’ questionnaire 
responses.28 Interviews were conducted by a postdoctoral 
research fellow (AG) experienced in qualitative research 
and trained in use of NVivo software (QSR International, 
USA) for qualitative analysis, with background in the field 
of health psychology. Field notes were made following 
every audio- recorded interview. Interview recordings 
(mean=52 min, SD=13.4, range=31–76) were transcribed.
Patient and public involvement
Patients were involved in the development of the ATTOM 
project objectives and procedures, as well as analysis and 
dissemination. A patient representative from the National 
Kidney Federation was involved in all aspects of the devel-
opment of the research. A patient representative was 
also invited to all steering group meetings throughout 
Figure 1 CONSORT (Consolidated Standards of Reporting Trials) diagram.  
ATTOM, Access to Transplantation and Transplant Outcome Measures; DDKT, DD kidney transplantation; LDKT, LD kidney 
transplantation; m, month.
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the duration of the project. Findings were presented to 
patients and lay people as part of an NIHR (National Insti-
tute for Health Research) stakeholder ATTOM meeting 
in November 2017.
Outcomes
A summary of the primary outcome measures can be seen 
in online supplemental data 2, table 1. QoL was assessed 
using the RDQoL questionnaire,21 developed from the 
ADDQoL questionnaire.22 29 It includes one overview item 
to measure generic QoL on a scale from excellent (+3) 
to extremely bad (−3). Twenty- one items measure the 
impact of the renal condition on specific aspects of life. 
Each specific item includes a rating of the impact of the 
renal condition on QoL, from −3 (most negative impact) 
to +1 (positive impact), and a rating of importance of 
that aspect of life for the individual’s QoL ranging from 
very important (+3) to not at all important (0). Impact 
and importance ratings are multiplied to give a weighted 
impact score for each item, ranging from −9 (most nega-
tive/important impact of the renal condition on QoL) 
to +3 (most positive/important impact). Some items 
include preliminary questions to determine applicability 
to the individual (eg, work). The weighted impact scores 
are summed and divided by the number of applicable 
items to give an AWI score, also ranging from −9 to +3. 
Principal axis factoring and reliability analyses confirmed 
that the RDQoL was appropriate for both transplant and 
non- transplant groups (see online supplemental data 3, 
tables 2–4).
Well- being was measured by the Well- being Question-
naire (W- BQ12).30 Higher scores indicate greater well- 
being (range=36-0). Health status was measured by the 
EQ- 5D- 5L,31 which has two sections. The first section 
includes five dimensions of health that are rated on five 
levels. These data were then converted into a popula-
tion preference score called a health- utility value, using 
the new value set for England.32 The second section 
asks participants to rate 'Your health today' on a visual 
analogue scale (EQ- VAS) from 100 (best health you 
can imagine) to 0 (worst health you can imagine). The 
EQ- VAS is a PROM, but the utility measure is not, as it 
depends not only on patients' reports but also on the 
values assigned by the general population to each profile 
of scores for the five dimensions of health used to create 
the value set for England.
Satisfaction with current renal treatment was measured 
using the Renal Treatment Satisfaction Questionnaire 
status version (RTSQs).33 It has 13 items, with 7- point 
scales (6 to 0), that are summed to give a total score 
(range=78–0). Higher scores indicate greater satisfac-
tion with current renal treatment. The change version 
(RTSQc) is modelled on the change version of the Diabetes 
Treatment Satisfaction Questionnaire (DTSQc),34 devel-
oped to counteract ceiling effects found with the status 
version (DTSQs).35 It asks participants to compare satis-
faction with current treatment with satisfaction with their 
previous treatment on 7- point scales (+3 to −3 where 0=no 
change) and is summed to give a total score from +39 
(maximum satisfaction improvement) to −39 (maximum 
deterioration in satisfaction). Principal axis factoring and 
reliability analyses confirmed that the RTSQs and RTSQc 
were appropriate for both transplant and non- transplant 
groups (see online supplemental data 3, tables 5–6).
For access to the RDQoL, ADDQoL, RTSQs and 
c, DTSQs and c, and Well- being Questionnaire, visit 
https://www. heal thps ycho logy research. com/. For access 
to EQ- 5D visit https:// euroqol. org/.
All sociodemographic and medical information was 
recorded by research nurses from medical notes at 
the time of recruitment. Any condition mentioned in 
patients’ records was identified and classified into groups 
(heart disease, heart failure, liver disease, diabetes, mental 
health problems, peripheral vascular disease). Prescribed 
immunosuppressant and steroid medication were also 
recorded. Height and weight were recorded to allow 
calculation of body mass index (BMI). Any subsequent 
changes to information (such as change from being on 
the WL to receiving a transplant) were self- reported by 
participants.
Analysis
Reflecting previous research in this area, the main 
analyses involved cross- sectional differences at 1 year 
follow- up in those who received a DD transplant (n=145), 
LD transplant (n=120) and those who remained waiting 
for a transplant (n=98) at 1 year follow- up. These anal-
yses were conducted using one- way analysis of covariance 
(ANCOVA), controlling for medical and demographic 
differences recorded at recruitment. Clinical factors such 
as previous renal replacement therapy, as well as demo-
graphic factors including age, and indicators of socioeco-
nomic status (such as car ownership and qualifications), 
can influence a person’s perspective on their QoL and 
treatment satisfaction. We therefore assessed these vari-
ables and controlled for them in the analyses if differences 
between groups were identified (using χ2 tests or analysis 
of variance).36 It was hypothesised that patients still on 
the WL would have more negative scores on PROMs than 
those who received a transplant.
Secondary analyses involved a prospective assessment 
of those participants recruited as patients on the WL 
(n=165). The sample was divided into three groups based 
on their treatment at follow- up; those who remained 
waiting for a transplant (n=98); those who subsequently 
had a DD (n=41); and those who subsequently had an LD 
transplant (n=26). This allowed for changes in outcomes 
to be measured pre- transplant and post- transplant for 
these groups and for pre- transplant differences to be 
controlled for. Differences between groups and over time 
were investigated with a series of 3 (group) x 2 (time) 
ANCOVAs with planned comparisons on all PROMs and 
utility outcome scores (controlling for various factors). 
It was hypothesised that those who received a transplant 
would report improved PROMs, while those remaining 
on the waiting list would report either no change, or a 
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deterioration in scores. It was also hypothesised that when 
differences in sociodemographic factors are controlled, 
there will be no differences in outcomes between DD and 
LD recipients. A one- way ANCOVA was also conducted 
to examine differences between these three groups 
(those who remained on the WL, those who subsequently 
had a DD or LD transplant) for change in satisfaction 
comparing treatment at 1 year (eg, 1 year post- transplant) 
with previous renal treatment (eg, dialysis at recruitment) 
using RTSQc scores.
For the qualitative interview data,37 thematic analysis 
based on a pragmatic and critical realist approach was 
used to explore the experiences of transplant recipients. 
Field notes were reviewed and transcripts read three 
times for familiarisation prior to analysis. The coding was 
completed in Microsoft Word, then entered into NVivo 10 
software for analysis. Using established guidelines,38 inde-
pendent initial coding by AG established major themes 
derived from the data which enabled development of a 
coding framework (AG, CB and MC). There was substan-
tial coder agreement (AG and JB) on five interviews; AG 
completed the remaining coding on subsequent inter-
views. Reiteration of responses indicated data saturation 
had been achieved after 20 interviews.
RESULTS
Descriptive findings
Descriptive data for the groups at recruitment (165 
patients recruited while on WL for a kidney transplant, 
104 DD recipients and 94 LD recipients) are shown in 
table 1. Almost 13 per cent (12.5%) of DD recipients and 
47.5% of LD recipients received their transplants before 
requiring dialysis. Almost 18 per cent (17.6%) of those 
on the WL were not yet on dialysis when recruited to the 
study. At recruitment, 47 (28.5%) patients on the WL 
had had a previous kidney transplant that failed, while 
13 LD (13.8%) and 12 DD (11.5%) recipients had had a 
previous transplant.
Of all those who received a DD transplant during the 
study, 80 (55.2%) received a kidney from a donor after 
circulatory death (DCD), and 65 (44.8%) received a 
kidney from a donor after brain death (DBD). Sixty- nine 
LD recipients (57.5%) received a kidney from a relative 
(35 from parent or adult child, 24 from a sibling and 10 
from another relative, eg, aunt, uncle, niece, nephew, 
cousin), while 51 (42.5%) received a genetically unre-
lated donor kidney (via the paired/pooled exchange or 
altruistic donors).
In total, 82 (22.6%) participants did not complete 
measures at 1 year; 33 (9.1%) were not contactable, 39 
(10.7%) did not return questionnaires and 10 were known 
to have died (2.8%). Responders at 1 year were older 
(t(120.55)=−2.4, p=0.017), and had better EQ- VAS health 
ratings (t(347)= −2.9, p=0.005) at recruitment compared 
with non- responders. There were no differences in sex, 
employment status, civil status, education or previous 
RRT between those who did and did not respond at 
1 year. Responders at 1 year were more likely to be white 
(χ2=10.3, df=4, p=0.016) than non- responders. Missing 
data were fewer than 5% for all variables and were missing 
at random, so cases were deleted analysis by analysis.
For those 20 participants who took part in the quali-
tative interviews: 10 were women; 13 were living with a 
partner or married, 4 were single and 3 were separated 
or divorced; 9 were working, 8 were retired and 3 were 
unemployed/long- term disabled; 6 had had a previous 
transplant; and 17 were white with the remaining 3 partic-
ipants being Chinese, Asian or identified as mixed race; 6 
were transplanted before requiring dialysis, 12 were previ-
ously on haemodialysis and 2 received peritoneal dialysis 
prior to transplant.
Quantitative findings
LD recipients were significantly younger compared with 
the other groups (F(3, 375)=9.7, p<0.001; see table 1). The 
majority of DD recipients and patients on the WL were on 
haemodialysis, while a larger proportion of LD recipients 
were transplanted before commencing dialysis (χ2=23.3, 
df=2, p<0.001). LD recipients were more likely to own a 
car (χ2=6.9, df=2, p=0.032). Those who remained on the 
WL differed from those who received a transplant on two 
marginally related factors (r=0.11, p=0.039); patients on 
the WL were more likely to have experience of a previous 
transplant that failed (χ2=16.8, df=2; p<0.001) and experi-
ence of mental health problems (as recorded by research 
nurses from medical notes; χ2=8.9, df=2; p=0.011). DD 
recipients and participants on the WL reported fewer 
educational qualifications than LD recipients (χ2=13.7, 
df=6, p=0.033). All subsequent analyses controlled for 
age, previous RRT, previous experience of a transplant, 
education, car ownership and history of mental health 
problems. Participants who were classified as obese at 
recruitment (BMI >30) or had a diagnosis of diabetes 
were more likely to experience worse QoL than those 
without either condition (p<0.05). In separate research 
conducted as part of the ATTOM programme, obesity was 
associated with a greater likelihood of delayed graft func-
tion in DD transplant recipients, and diabetes was related 
to a greater risk of transplant failure in LD transplant 
recipients.39 Analyses were therefore run controlling for 
obesity and diabetes. The difference in generic QoL at 
baseline in those patients who remained on the WL and 
who did not go on to receive a transplant disappeared, 
but the sample size was reduced by 16 participants. 
There were no meaningful differences in the outcomes 
at 12- month follow- up in the analyses that did and did 
not control for these factors, so reported findings do not 
control for obesity and diabetes.
Table 2 shows the correlations between the main 
outcome variables at 12- month follow- up. Table 3 shows 
the cross- sectional differences at 1 year post- recruitment/
post- transplant between those who remained on the WL 
for a transplant (n=98), and those who received a DD 
(n=145) or LD transplant (n=120). Participants on the 
WL reported significantly worse scores on all PROMs 
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Table 1 Summary of baseline demographic characteristics of groups at recruitment
Variable
Wait- list group (n=165) DD recipients (n=104) LD recipients (n=94)
P valueM (SE) M (SE) M (SE)
Age* in years 50.7 (1.6) 51.1 (1.3) 43.9 (1.4) <0.001
Time on waiting list in days 980 (124.9) 953 (284.9) 990 (414.4)† 0.995
Sociodemographic variables N (%) N (%) N (%) P value
Age* <0.001
  18–34 25 (15.1) 12 (11.5) 29 (30.9)
  35–49 46 (27.9) 32 (30.8) 32 (34.0)
  50–64 66 (40.0) 41 (39.4) 27 (28.7)
  65–75 28 (17.0) 19 (18.3) 6 (6.4)
Sex: Female 59 (35.8) 40 (38.5) 34 (36.2) 0.949
Ethnicity 0.411
  White 134 (81.2) 84 (80.8) 85 (90.4)
  Black 15 (9.1) 10 (9.6) 5 (5.3)
  Asian 1 (0.6) 1 (1.0) 0 (0.0)
  Chinese 13 (7.9) 7 (6.7) 3 (3.2)
  Mixed 2 (1.2) 2 (1.9) 1 (1.1)
Marital status 0.462
  Single 32 (19.4) 20 (19.2) 27 (28.7)
  Married/living with partner 98 (59.4) 63 (60.6) 60 (63.8)
  Divorced/ separated/ widowed 35 (21.2) 121 (20.2) 7 (7.5)
Education 0.166
  No qualifications‡ 32 (19.4) 16 (15.4) 8 (8.5) 0.033
  Basic (GCSE/ A level/NVQ 1–3) 94 (57.0) 66 (63.5) 68 (72.3)
  Higher (degree/ higher degree/ NVQ 4–5) 39 (23.6) 22 (21.1) 18 (19.2)
Car ownership: Yes 134 (81.2) 89 (85.6) 90 (95.7) <0.000
Clinical variables
Primary renal diagnosis 0.515
  Diabetes: Type 1 or 2 9 (5.5) 11 (10.6) 5 (5.3)
  Glomerulonephritis 50 (30.3) 32 (30.8) 42 (44.7)
  Interstitial nephritis/ pyelonephritis 21 (12.7) 13 (12.5) 16 (17.0)
  Hypertension/ large vessel disease 10 (6.1) 8 (7.7) 0 (0.0)
  Cystic/ hereditary/ congenital disease 47 (28.4) 19 (18.3) 14 (14.9)
  Other conditions 28 (17.0) 21 (20.1) 17 (18.1)
Comorbid conditions
  Diabetes 20 (12.2) 16 (15.4) 8 (8.5) <0.005
  Heart disease 19 (11.6) 6 (5.8) 7 (7.4) 0.006
  Heart failure 6 (3.7) 4 (3.8) 0 (0.0) 0.305
  Liver disease 4 (2.4) 3 (2.9) 1 (1.1) 0.299
  Mental health problems 14 (8.5) 2 (1.9) 5 (5.3) 0.022
  Obesity (BMI >30) 32 (19.5) 22 (21.2) 14 (14.9) 0.600
Previous renal replacement therapy <0.001
  No dialysis** 29 (17.6) 13 (12.5) 43 (45.7)
  Peritoneal dialysis 27 (16.4) 23 (22.1) 14 (14.9)
  Haemodialysis (HD)§ 109 (66.0) 68 (65.4) 37 (39.4)
  Central venous catheter 35 (53.1) 31 (55.6) 21 (56.8)
  Arteriovenous fistula 22 (33.3) 28 (41.2) 15 (40.5)
  Unknown 9 (13.6) 9 (13.2) 1 (2.7)
Continued
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at 1 year compared with the two transplant groups (all 
p<0.001). LD recipients reported better generic QoL, 
RDQoL, well- being and treatment satisfaction (all 
p<0.05) than DD recipients. These analyses suggest that 
LD recipients have better outcomes than DD recipients 
post- transplant, but do not consider baseline differences 
in PROMs pre- transplant.
Table 4 and figure 2 depict the prospective analyses 
comparing over time, those who remained on the WL 
(n=98) and those who were recruited as patients on the 
Variable
Wait- list group (n=165) DD recipients (n=104) LD recipients (n=94)
P valueM (SE) M (SE) M (SE)
Previous transplant failure¶ 47 (28.5) 12 (11.5) 13 (13.8) 0.001
Highly sensitised: Yes 8 (4.9) 9 (8.7) 8 (8.5) 0.842
Donor related to patient: Yes – – 56 (59.6)
Induction suppression 0.116
  None – 16 (15.4) 19 (20.2)
  Anti- thymocyte globulin – 7 (6.7) 1 (1.1)
  Basiliximab – 66 (63.5) 53 (56.4)
  Campath – 15 (14.4) 21 (1.1)
Calcineurin inhibitor maintenance 0.073
  Tacrolimus – 98 (94.2) 93 (98.9)
  Ciclosporin – 6 (5.8) 1 (1.1)
Anti- proliferative drugs 0.341
  None – 13 (12.5) 8 (8.5)
  Mycophenolate – 70 (67.3) 54 (57.4)
  CellCept – 8 (7.7) 16 (17.0)
  Myfortic – 7 (6.7) 10 (10.6)
  Azathioprine – 6 (5.8) 6 (6.4)
Steroid maintenance plan 0.193
  None – 9 (8.7) 12 (12.8)
  Withdraw within 3 months – 18 (17.3) 24 (25.5)
  Long- term use – 77 (74.0) 58 (61.7)
303132
*LD recipients were younger.
†Figures here reflect only those who were on the WL for a DD transplant before receiving a LD transplant (n=16).
‡Fewer LD recipients reported no educational qualifications.
§More DD recipients and patients on the WL reported being on HD prior to transplantation/listing.
¶WL patients reported more previous transplant failures.
**A larger proportion of LD recipients were transplanted pre- emptively.
BMI, body mass index; DD, deceased- donor transplant; LD, living- donor transplant; M, mean; PROM, patient- reported outcome measure; WL, 
waiting list group.
Table 1 Continued
Table 2 Correlations between outcome measures at 12- month follow- up for all participants
Variable 1 2 3 4 5 6
1 Generic QoL –
2 Renal- dependent QoL 0.499*** –
3 Well- being 0.740*** 0.551*** –
4 Health status (EQ- VAS) 0.725*** 0.415*** 0.652*** –
5 Health- utility values 0.674*** 0.444*** 0.678*** 0.612*** –
6 Renal treatment satisfaction (RTSQs) 0.545*** 0.420*** 0.521*** 0.454*** 0.364*** –
7 Change in treatment satisfaction (RTSQc) 0.282*** 0.134* 0.292*** 0.293*** 0.125* 0.617***
*p<0.05, **p<0.01, ***p<0.001.
EQ- VAS, EuroQoL Visual Analogue Scale; QoL, quality of life; RTSQc, RTSQ change version; RTSQs, Renal Treatment Satisfaction 
Questionnaire status version.
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WL, but who subsequently received a LD (n=26) or DD 
transplant (n=41). There were significant interaction 
effects between the three groups and from recruitment 
to 1 year post- recruitment/post- transplant for all PROMs. 
At recruitment, patients on the WL who did not go on 
to receive a transplant reported worse generic QoL than 
Table 3 Summary of adjusted means, standard errors and main effects examining cross- sectional differences in groups 
in patient- reported outcomes at 1 year, controlling for age, previous renal replacement therapy, previous experience of a 
transplant, education, car ownership and mental health problems
Wait- list group DD transplant LD transplant
F df P value Partial η2Mean (SE) 95% CI Mean (SE) 95% CI Mean (SE) 95% CI
Generic QoL*† 0.4 (0.1) 0.1 to 0.7 1.4 (0.1) 1.1 to 1.6 1.8 (0.1) 1.5 to 1.9 27.6 266 <0.001 0.20
Renal- dependent QoL*† −4.4 (0.3) −4.9 to −3.9 −2.7 (0.2) −3.1 to −2.4 −1.9 (0.2) −2.3 to −1.5 27.2 266 <0.001 0.18
Well- being* 19.0 (0.9) 14.3 to 20.8 24.9 (0.7) 23.7 to 26.3 27.4 (0.8) 25.8 to 28.9 24.7 265 <0.001 0.17
Health status (EQ- VAS)* 62.4 (2.2) 58.0 to 66.8 77.9 (1.6) 74.8 to 81.2 82.4 (1.9) 78.7 to 86.1 24.1 263 <0.001 0.18
Health- utility values* 0.7 (0.1) 0.6 to 0.8 0.8 (0.1) 0.8 to 0.9 0.9 (0.1) 0.8 to 0.9 13.1 259 <0.001 0.11
Renal treatment 
satisfaction (RTSQs)*†
58.6 (1.3) 56.1 to 61.1 67.4 (0.9) 65.5 to 69.2 72.6 (1.1) 70.5 to 74.7 34.3 265 <0.001 0.21
Change in treatment 
satisfaction (RTSQc)*
14.1 (1.7) 10.8 to 17.4 29.2 (1.3) 26.7 to 31.7 30.9 (1.4) 28.2 to 33.8 33.6 253 <0.001 0.22
Partial η2 is a measure of effect size that measures the proportion of the total variance in a dependent variable that is associated with the 
membership of different groups defined by an independent variable, in which the effects of other independent variables and interactions are partialled 
out. Partial η2 is seen as giving small (0.01), medium (0.09) or large (0.25) effect sizes.
*WL group reported worse outcomes compared with DD or LD recipients (p<0.001).
†LD recipients reported better scores than DD recipients (p<0.05).
DD, deceased- donor transplant; EQ- VAS, EuroQoL Visual Analogue Scale; LD, living- donor transplant; M, mean; QoL, quality of life; RTSQc, Renal 
Treatment Satisfaction Questionnaire change version; RTSQs, RTSQ status version; SE, standard error; WL, waiting list.
Table 4 Summary of adjusted means, standard errors and interaction effects examining differences in those who remained 
on the waiting list and those who subsequently had a LD or DD transplant, in patient- reported outcomes from pre- transplant 
to 12 months post- transplant/recruitment to 12 months, controlling for age, previous renal replacement therapy, previous 
experience of a transplant, education, car ownership and mental health problems
Generic QoL
Renal- dependent 
QoL Well- being
Health status EQ- 
VAS scores
Health- utility 
values
Renal treatment 
satisfaction (RTSQs)
Recruitment
WL M (SE) 0.39 (0.15) −4.29 (0.27) 22.94 (0.78) 69.32 (2.63) 0.78 (0.03) 58.43 (1.76)
  CI 0.10 to 0.69 −4.82 to −3.75 21.40 to 24.48 64.10 to 74.53 0.73 to 0.83 54.94 to 61.93
DD M (SE) 1.11 (0.21) −3.98 (0.39) 23.18 (1.04) 67.42 (3.50) 0.86 (0.03) 60.10 (2.42)
  CI 0.69 to 1.52 −4.74 to −3.12 21.11 to 25.25 60.48 to 74.36 0.79 to 0.92 55.29 to 64.91
LD M (SE) 0.77 (0.27) −4.08 (0.49) 22.37 (1.40) 61.10 (4.27) 0.86 (0.04) 54.76 (3.15)
  CI 0.23 to 1.31 −5.06 to −2.15 19.59 to 25.15 51.78 to 70.42 0.77 to 0.94 48.50 to 61.01
12 months post- recruitment / 12 months post- transplant
WL M (SE) 0.39 (0.14) −4.45 (0.27) 18.95 (0.99) 61.89 (2.39) 0.69 (0.03) 59.11 (1.45)
  CI 0.11 to 0.68 −4.99 to −3.91 16.99 to 20.92 57.16 to 66.63 0.63 to 0.75 56.24 to 61.99
DD M (SE) 1.30 (0.20) −2.92 (0.39) 24.45 (1.33) 77.19 (3.18) 0.85 (0.04) 66.07 (1.99)
  CI 0.90 to 1.69 −3.68 to −2.15 21.81 to 27.09 70.88 to 83.49 0.76 to 0.93 62.12 to 70.03
LD M (SE) 1.77 (0.26) −2.41 (0.49) 27.30 (1.79) 83.90 (4.27) 0.93 (0.05) 74.07 (2.59)
  CI 1.25 to 2.28 −3.39 to –1.43 23.74 to 30.84 75.43 to 92.37 0.82 to 1.03 68.93 to 79.21
  F 5.91 12.08 14.43 20.63 8.04 15.25
  df 103 102 111 110 108 101
  P value 0.004 <0.001 <0.001 <0.001 0.001 <0.001
  Partial η2 0.10 0.19 0.21 0.27 0.13 0.23
DD, those recruited as wait- list patients, but who subsequently had a deceased- donor transplant; EQ- VAS, EuroQoL Visual Analogue Scale; LD, 
those recruited as wait- list patients, but who subsequently had a living- donor transplant; M, mean; QoL, quality of life; RTSQs, Renal Treatment 
Satisfaction Questionnaire status version; WL, those who remained on the waiting list from recruitment to 12m post- recruitment.
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those who went on to receive DD transplants (p=0.028). 
Patients who remained on the WL reported worsening 
EQ- VAS health ratings (p=0.004), utility values (p<0.001) 
and well- being (p<0.001) from recruitment to 1 year, but 
generic QoL, renal- dependent QoL and renal treatment 
satisfaction remained stable over time. In contrast, DD 
recipients reported improvements in EQ- VAS health 
ratings (p=0.017), renal- dependent QoL (p=0.011) and 
renal treatment satisfaction (p<0.001), but no change in 
utility values (p=0.450), well- being (p=0.380) or generic 
QoL (p=0.200) from pre- transplant to post- transplant. 
LD recipients reported improvements in all outcomes 
post- transplant (p<0.01). Though LD recipients reported 
greater treatment satisfaction than DD recipients 
(p=0.038), the transplant groups did not differ on any 
other PROMs post- transplant. Patients still on the WL 
reported worse scores on all PROMs at 1 year compared 
with both transplant groups (p<0.001). The effect sizes 
ranged from small to moderate (table 4; partial η2=0.10–
0.27). Worse generic QoL post- transplant was reported 
by 16% of DD recipients and 5% of LD recipients. In 
contrast, 7% of DD recipients and no LD recipients 
reported more negatively impacted AWI scores from 
pre- transplant to post- transplant. Similarly, 8% of DD 
recipients and no LD recipients reported worse health 
status as measured by the EQ- VAS from pre- transplant to 
post- transplant.
Using the treatment satisfaction scores from the 
RTSQs at recruitment as a further covariate in analyses, 
both DD (mean=29.6, SE=2.7) and LD recipient groups 
(mean=31.8, SE=3.4) reported greater satisfaction with 
renal treatment at 1 year versus previous treatment than 
those still on the WL (mean=14.4, SE=1.9; F(1, 97)=16.1, 
p<0.001; partial η2=0.25; figure 3).
Qualitative findings
Three themes were identified from the qualitative inter-
views; participants discussed the positive impact of trans-
plantation, the impact of expectations on the ability to 
cope post- transplant, and their feelings towards donors. 
Illustrative examples of quotations can be seen in table 5. 
Overall, participants viewed their transplant as a way to 
return to ‘normal’. Both transplant groups reported 
physical improvements, reduced dietary and fluid restric-
tions, and improved lifestyle post- transplant. Many 
Figure 2 Interaction graphs showing differences in outcomes at recruitment and at 1 year post- transplant/post- recruitment 
in those who remained on the WL for a kidney transplant (n=98), or those who were recruited as patients on the WL and 
subsequently received a DD kidney transplant (n=41), or a LD kidney transplant (n=26). Adjusted scores shown, controlling for 
age, previous RRT, previous experience of a transplant, education, car ownership and history of mental health problems. 
*p<0.05 WL vs DD, ***p<0.001 WL vs LD/DD. DD, deceased donor; LD, living donor; m, month; RRT, renal- replacement therapy; 
VAS, Visual Analogue Scale; WL, wait- list group.
Figure 3 Bar graph showing differences in satisfaction 
with current renal treatment compared with previous renal 
treatment at 1 year post- transplant/post- recruitment in those 
who remained on the waiting list for a kidney transplant, 
or those who received a DD or LD kidney transplant after 
recruitment. Adjusted scores shown, controlling for age, 
previous RRT, previous experience of a transplant, education, 
car ownership, history of mental health problems and RTSQs 
scores at recruitment.  
DD, deceased donor; LD, living donor; m, month; RRT, renal- 
replacement therapy; RTSQs, Renal Treatment Satisfaction 
Questionnaire status version.
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Table 5 Summary of qualitative themes with illustrative quotations
Theme Illustrative quotations
Positive impact of 
transplantation
Physical changes:
Uh, I feel a hell of a lot better. I was terribly, terribly ill, and I even look like me now. I didn’t look like me for 
quite a long time. I had yellow eyes and grey skin. There’s no doubt at all that it’s made a massive positive 
difference. Woman, non- related- LD transplant following HD.
My energy levels are amazing… my mates and that, they just couldn’t believe it. They said ‘god you look 
better than I do’. And I was full of life, I’m full of life. That’s the sort of euphoria that you need, that gradually, 
very gradually subsided to normality I suppose. But I was, I was almost hyper. I felt so good. Man, pre- 
emptive related- LD transplant.
Lifestyle:
Everything’s gone right back to normal now it’s fine… You go back to practically normal. Man, DD transplant 
following HD.
I feel a bit normal again you know yeah Woman, DD transplant following APD.
I’m back to how I was some years back. Woman, pre- emptive non- related- LD transplant.
It gives you more freedom to, to actually live the life that I wanted to live, before dialysis… me and my wife 
are planning our honeymoon because I missed that because I just hit dialysis after my wedding. So now… 
after all these years on dialysis, we can plan for the future. Man, DD transplant following HD.
Being able to work is massive for me and I can now work full- time and not only work full- time but own my 
own home which I wasn’t able to do before. Woman, non- related- LD transplant following HD.
I can just get up and do things without worrying… It is so much better than what it was before. Before I 
thought I was going to die, now ok I know I’m going to die but maybe hopefully in the future. So, I don’t 
worry about the little things anymore. Woman, DD transplant following HD.
I mean I can drink as much as I like now. That before you could only drink like 1 L a day and that. Woman, 
DD transplant following HD.
I mean I’ve gone back; I have a normal diet now. Man, non- related- LD transplant following APD.
Impact of expectations 
on ability to cope post- 
transplant
Physical changes:
I have to drink like a fish. So, I’m all bloated … all I’ve got to show for (the transplant) is a huge stomach, 
because obviously they fitted a kidney in and the bag in my bladder so I look like I’m pregnant all the time… 
I’m a bit of a recluse actually. I just stay in all the time or if I was going out I can’t, I can’t wear anything fitted 
anymore because I look pregnant. Just, it’s really, rubbish! Woman, pre- emptive DD transplant.
I’ve lots of marks on my face (from a reaction to the medication) which isn’t the greatest thing for confidence 
in the world. Man, related- LD transplant following HD.
I'm on steroids so I have put on a bit of weight. Man, pre- emptive DD transplant.
There’s a thing when you have a transplant that you tend to pile it on, pile the weight on quite badly. 
Woman, non- related LD transplant following HD.
You have to take a lot of water … after your transplant. You’re supposed to take 2 L every day…I find I’m 
running to the toilet a lot. It breaks your sleep at night, you’re up maybe three times during the night and 
you’re waking up and you’ve not really properly slept. Man, pre- emptive related- LD transplant.
I hadn’t used my bladder for 7 years, and it was pretty darn painful (to use it again) and took a lot of running 
to the loo every 5 min. Woman, DD transplant following HD.
Then oh god I was weeing for Britain! You know, it was, that was something I found very hard to get used 
to because as you know your bladder would have shrunk to nothing … when I had the transplant, I had to 
drink 6 L. I found that quite hard. Woman, DD transplant following HD.
When you’re on dialysis you dream of being able to drink. Once you’re told you have to drink its actually 
really difficult…. It’s become normal not to drink anything and then all of a sudden, you’re told to drink at 
least 3 or 4 L of water or fluid a day. Woman, non- related- LD transplant following HD.
I’m still a little bit sort of behind where I would be but I’ve got like 30, I’ve got 35% function which is a little 
bit beyond where I need to be feeling properly sort of strong and active. But I’ve had a year of it being sort 
of, it’s never been really bad but I’ve had a year of it being not quite where it needs to be so I’m a lot more 
tired than I’d like to be. Man, DD transplant following HD.
I’ve just not got the stamina I had before like you know. Man, non- related- LD transplant following APD.
Continued
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DD recipients had not yet returned to work, but some 
LD recipients reported improvements related to their 
employment, due to their increased physical ability.
Patient expectations of transplantation had a strong 
influence on whether or not patients felt their trans-
plant was successful. Many patients believed that once 
they received a transplant, they would return to the same 
level of physical health they experienced prior to their 
kidney problems. Six out of the 10 LD recipients reported 
ongoing physical problems at 1 year post- transplant, such 
as reduced stamina, which they did not anticipate. This 
led to more difficulty adjusting post- transplant, and lower 
rates of treatment satisfaction. An unexpected side effect 
of transplantation included changes in physical appear-
ance, such as scarring, bloating from the surgery or 
weight gain from medication. Patients who experienced 
these changes found it harder to cope, and their QoL 
was negatively impacted. Other unexpected experiences, 
such as difficulty adapting to drinking large quantities 
of fluids and relearning bladder control post- transplant, 
were issues that participants found particularly difficult.
Although all participants reported feeling immense 
gratitude to their donors, LD recipients worried about 
the health of their donors, leading to feelings of guilt 
up to 1 year post- transplant. This was particularly evident 
in three recipients whose donors were their adult chil-
dren. Continued worry about their donors meant that 
LD recipients were likely to report difficulties in coping 
post- transplant.
DISCUSSION
Previous research has shown consistently that there are 
differences in the patient characteristics of DD and LD 
recipients.14 15 40 Controlling for such factors, our cross- 
sectional analyses suggest that LD transplantation conveys 
an advantage over DD transplantation for QoL and treat-
ment satisfaction. However, once baseline differences 
in factors such as age, education and time on dialysis 
were controlled for (in the subset of patients with true 
baseline measures pre- transplant), DD and LD kidney 
transplant recipients are found to have similar outcomes 
post- transplant. The only significant difference between 
transplant groups with true baseline data was in treat-
ment satisfaction 1 year post- transplant with LD recipients 
having greater treatment satisfaction than DD recipients. 
Previous research showed that LD recipients reported 
greater improvements within the first few months post- 
transplant, but LD and DD recipients did not differ after 
longer intervals of time.17 Although the improvements 
seen in the LD recipients are encouraging, our results 
suggest that they have worse baseline measures of treat-
ment satisfaction, health status and generic QoL before 
transplant, so their improvements post- transplant are 
Theme Illustrative quotations
I know it’s taken me a whole year to really be as I was before and I still feel in some ways I’m not quite back 
to what I was before. Woman, pre- emptive non- related- LD.
My metabolism seems to have changed a great deal from the moment I had the transplant. Woman, related- 
LD transplant following HD.
I've always wanted to try out cabin crewing before but now I can't even think of doing it because of my 
health conditions cos I can deteriorate if I start to fly. I have to be very cautious about what I want, you know 
like what I choose now, just to have to be very careful basically, even holidays. It’s just very depressing. 
Woman, DD transplant following PD.
Feelings towards donor Gratitude:
I’m so grateful for having it. Man, DD transplant following HD.
I’m very lucky to get the chance, due to my donor like; you know to get a chance of living again, and being 
without dialysis. Woman, DD transplant following PD.
I mean I really, I’m incredibly, incredibly lucky I’ve got this person who I don’t know, somewhere in the world, 
somewhere in the UK, I don’t know where, to thank for this change of my, total change of my life. Woman, 
non- related- LD transplant following HD.
Worry:
Psychologically I would rather have had a dead donor. For the simple reason that you know, it’s difficult to 
deal with taking a part of your daughter’s body out which she may need in later years. She was 27 at the 
time. So… it was very difficult, very difficult. Man, pre- emptive related- LD transplant.
She’s an only child and she has two children of her own and (it’s) such a sacrifice and if anything had gone 
wrong or even now if anything happens to her and her other kidney, … I worry about her. Woman, related- 
LD transplant following HD.
You worry about the future you know. My (donor) she’s very young, she’s all of her life and that you know. 
Man, pre- emptive related- LD transplant.
DD, deceased donor; LD, living donor; HD, haemodialysis; PD, peritoneal dialysis; APD, automated peritoneal dialysis.
Table 5 Continued
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more evident. Caution should be exercised when inter-
preting studies that have not controlled for differences 
at recruitment and rely on cross- sectional follow- up data 
alone.
The qualitative interviews show that although partic-
ipants report improvements to their QoL through 
a return to ‘normal’ and improvements in lifestyle, 
participants still experience ongoing negative impact. 
Although transplantation is considered a positive and 
successful treatment, it cannot minimise the negative 
impact of a renal condition completely. The findings 
reflect those of previous studies, which report that 
some transplant recipients find it difficult to adjust and 
cope post- transplant.41–43 Differing themes emerged for 
the LD and DD recipients; Although slightly more LD 
recipients had returned to work by 1 year (5/10 LD vs 
3/10 DD), they were more likely to mention difficulties 
in adapting post- transplant and feel that their positive 
expectations for recovery and return to work were not 
realised. Most LD recipients were not on dialysis before 
they received their transplant, so the benefits they 
perceived from transplantation were fewer than those 
who have experienced dialysis. It is important to manage 
patient expectations (eg, recovery times) to avoid disap-
pointment and promote effective coping with physical 
and psychosocial changes following transplant. A small 
number of LD recipients reported experiencing feel-
ings of guilt about the risks to their donors, as has been 
found elsewhere.14 15 Further support may be required 
for those considering such a transplant, to help antici-
pate and manage the potential for the feelings of guilt 
which may include deciding to decline the offer. The 
impact of transplantation on QoL and other PROMs on 
both recipients and their donors need to be considered, 
especially when assessing the comparative benefit of LD 
versus DD transplantation.
In line with our hypotheses, patients on the WL reported 
worse health and well- being over time. This may in part 
be due to the fact that almost 18% of those on the WL 
were not yet on dialysis when recruited to the study but all 
required dialysis 1 year later. Some patients may find that 
their health improves once they commence dialysis, but on 
average health status declined. However, QoL and treat-
ment satisfaction scores did not change over the course of 
12 months in those on the WL despite their deteriorating 
health status and well- being. This study cannot explain in 
detail the whole experience of patients on the WL for a 
transplant, and due to the relatively small sample size and 
small effect sizes for some of the outcomes, some of the 
results may not have been adequately powered. The lack 
of differences between groups over time therefore needs 
to be considered with caution. Despite this, the results 
highlight differences between health status and QoL.20 
QoL can be affected by multiple aspects of people’s lives 
with their health being just one aspect, so it is important to 
distinguish between measures of genuine QoL and health 
status when selecting and interpreting the results from 
PROMs. This is particularly the case where the treatment 
for long- term conditions such as CKD may benefit health 
status but may impair QoL.
There are some limitations to this study. The sample of 
transplant participants with pre- transplant data was relatively 
small (n=67), as they were part of secondary analyses, some of 
which may be underpowered, so caution needs to be exercised 
when drawing conclusions. However, the findings provide 
insight into how QoL and other patient- reported outcomes 
change over time in transplant recipients. Only those fluent 
in English were recruited to ensure that participants could 
complete the questionnaires: cost of linguistic validation for 
all the PROMs to be translated into other languages exceeded 
the ATTOM programme’s resources. This meant that, for 
example, few people of South Asian descent took part in our 
substudy, despite the fact that approximately 9.4% of trans-
plant recipients recruited to the larger ATTOM research 
programme were of Asian ethnicity (with the great majority 
being of South Asian descent). Those interviewed for the 
qualitative interviews were mainly white. Therefore, the 
sample is less ethnically diverse than the UK renal population 
as a whole. Patients who responded at 1 year were more likely 
to be older, white and have better health ratings at recruit-
ment, so our findings may not be generalisable to younger 
non- white patients, and may give a more positive view of 
changes in health over time than if those with worse base-
line health status were included. Ten patients were known to 
have died during the study period and no one reported a 
failed transplant during data collection, limiting the scope of 
the findings to those who remained healthy enough to be 
on the WL, and those with a functioning graft. Despite this, 
participants to our PROMs substudy were recruited as part 
of ATTOM from renal units across the UK, reflecting the 
full ATTOM sample in terms of age, sex, previous transplant 
and rate of pre- emptive transplantation. Most patients had 
not returned to work at follow- up; those who had returned 
to work had varying levels of QoL compared with those who 
had yet to return to work. The long- term impact of taking 
immunosuppressants, including the increased risk of cancer 
and other diseases, may not yet be reflected in participants’ 
QoL and other PROMs within the first year of having a trans-
plant. Longer follow- up, therefore, may be required to show 
any differences across transplant groups, and the long- term 
impact of immunosuppressant medication on QoL. The 
focus of this study was on PROMs, but medical variables 
such as the number of complications post- transplant which 
may impact on QoL, were not assessed. Nevertheless, this is 
one of the few studies that provide any pre- transplant data, 
allowing us to examine changes over time in transplant recip-
ients and, importantly, to control for baseline differences 
in PROMs. Additionally, the inclusion of patients on the 
WL along with recipients of LD and DD in analyses which 
controlled for group differences, allowed for direct compar-
ison of outcomes for transplant recipients and those still on 
the WL. The paper highlights the importance of measuring 
and controlling for pre- existing differences between groups. 
A strength of this study is that it included both qualitative and 
quantitative data, which allowed for further understanding 
of the subjective experience of transplantation. It also shows 
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that examining a range of PROMs provides a much better 
understanding of the experience of waiting for or receiving a 
transplant than is provided by health- status measures alone.
These findings have implications for clinical practice 
including future monitoring of patient- reported outcomes. 
Both transplant groups reported better outcomes than 
those still on the WL for a transplant, but there were few 
differences in PROMs between groups post- transplant after 
adjustment for potential confounders. Living donation has 
certain medical advantages, including that recipients do not 
have to wait as long for the transplant, but it is also important 
to acknowledge that living donation does not just affect 
recipients and their donors physically. Discussion is needed 
about more than just the medical benefits for the recipient 
and the medical impact on the donor; PROMs need to be 
better integrated into the information provided to recipients 
and donors when transplantation is discussed as a treatment 
option. Knowing that not all patients report improvements 
in PROMs and why may help future patients avoid disap-
pointment. Routine collection of PROMs data at time of wait- 
listing and periodically thereafter is required so that a more 
accurate picture of changes pre- transplant to post- transplant 
can be achieved from larger more representative data sets. 
Careful expectation management, information on recovery 
time, anticipated physical changes (including scar size) and 
side- effects may help avoid disappointment and ensure better 
informed decisions about transplantation options. Never-
theless, both transplant types were, overall, more beneficial 
than remaining on the WL and may be considered similarly 
advantageous in improving QoL and other patient- reported 
outcomes.
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